Candriam S.C.A. I Mab Transaction History
Candriam S.C.A.
- $15.4 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding IMAB
# of Institutions
45Shares Held
16MCall Options Held
11.9KPut Options Held
3.5K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$10.8 Million0.29% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$6.5 Million3.04% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny617KShares$962,6760.0% of portfolio
-
Two Sigma Investments, LP New York, NY576KShares$897,9040.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$883,9740.01% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $130M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...